Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patritumab Deruxtecan in Metastatic Colorectal Cancer
NCT04479436Phase 2Terminated
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Sep 2020
- Primary completion
- Feb 2022
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 2 trial of patritumab deruxtecan in metastatic colorectal cancer (mCRC), sponsored by Daiichi Sankyo Co., Ltd.. Started Sep 2020; status: terminated.
02
Drugs
patritumab deruxtecan
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT04479436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04479436.